2. Academic Validation
  3. A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection

A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection

  • Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6. doi: 10.1016/j.bmcl.2004.02.101.
David W Borhani 1,  David J Calderwood,  Michael M Friedman,  Gavin C Hirst,  Biqin Li,  Adelaine K W Leung,  Brad McRae,  Sheldon Ratnofsky,  Kurt Ritter,  Wendy Waegell
Affiliations

Affiliation

  • 1 Abbott Bioresearch Center, 100 Research Drive, Worcester, MA 01605-5314, USA.
PMID: 15109663 DOI: 10.1016/j.bmcl.2004.02.101
Abstract

We have identified the pyrazolo[3,4-d]pyrimidine A-420983 (compound 7) as a potent inhibitor of Lck. A-420983 exhibits oral efficacy in animal models of delayed-type hypersensitivity and organ transplant rejection.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-136622
    Lck Inhibitor
    Src